Table 1.

Characteristic of patients with COVID-19 (n = 67) and difference between patients who were not hospitalised, hospitalised without ICU and with ICU treatment.

	All	Group I	Group II	Group III	p-Value (between Groups) #
N	67	12	40	15
Age, years	52.7 ± 14.8	41.8 ± 8.5	54.2 ± 15.6	57.7 ± 12.5	0.012 A
Sex, male	39 (58.2)	3 (25.0)	24(60.0)	12 (80.0)	0.016 B
CCI *†	2 [1;3]	1 [0;2]	2 [0;>3] *	2 [2;>3]	0.073
CAT score *	5 [2;8]	2 [1.5;5.5]	5 [1;6] *	8 [2;10]	0.084
Co-morbidity	36 (53.7)	1 (8.3)	21 (52.5)	14 (93.3)	<0.001 C
Anticoagulation treatment **	29 (46.0)	1 (12.5) **	13 (32.5)	15 (100)	<0.001 D
Before diagnosis **	3 (4.8)	0 (0.0) **	3 (7.5)	0 (0.0)
After diagnosis **	26 (41.3)	1 (12.5) **	10 (25.0)	15 (100)
Time from positive SARS CoV-2 PCR test to 3 months follow-up, days	154 [132;191]	175.5 [150;222]	154 [120;187.5]	151 [141;170]	0.349
Time from discharge to follow-up, days ***	130 [98;167]	N/A	139.5 [98;174] ***	113 [95;140]	0.203

Data are expressed as mean ± SD, median [interquartile range] or n (%) as appropriate. CAT score: chronic obstructive pulmonary disease assessment test. † Charlson Comorbidity Index (CCI) values > 3, were recorded as 4 for calculation of the median. * Missing data from one patient (n = 66). ** Missing data from four patients (n = 63). *** Missing data from two patients (n = 53). # Fisher’s exact test, Wilcoxon rank-sum test, Kruskal-Wallis H test or one-way ANOVA where appropriate and if significant followed by bivariate comparison with Bonferroni correction for multiple comparisons. ^A: Difference between not hospitalised and hospitalised without ICU, and not hospitalised and hospitalised with ICU. ^B: Difference between not hospitalised and hospitalised with ICU. ^C: Difference between all groups. ^D: Difference between not hospitalised and hospitalised with ICU and hospitalised without ICU and hospitalised with ICU.